Editor's note: Adam Feuerstein will be the featured guest on TSC Live at noon EDT today, Sept. 29. Email your questions at tsclive@thestreet.com; tweet us on Twitter with hash tag #tsclive; or leave a message on our Facebook page. Bookmark the TSC Live page now.

(Updated with Elan's SEC inquiry)

THE WOODLANDS, Texas ( TheStreet) -- More bad news for Repros Therapeutics ( RPRX): The Food and Drug Administration asked the company for more clinical data on its experimental uterine fibroid drug Proellex. At the same time, regulators expressed doubts that Repros will ever be able to determine a dose of the drug that can be effective and safe.

As a result, Repros said it would try to license Proellex to another company.

Repros stopped clinical trials of Proellex in July and August after some patients taking the drug were diagnosed with elevated liver enzymes, a potentially dangerous side effect that could lead to permanent liver damage.

Repros shares were trading around $7 this summer but have plunged to below $1 a share in recent trading.

Elan in Two Financing Deals, Discloses SEC Inquiry

Elan, fresh off renegotiating its Alzheimer's licensing agreement with Johnson & Johnson, announced steps Tuesday to further clean up its balance sheet and the receipt of a subpoena from the Securities and Exchange Commission.

The Irish drug maker announced a cash tender offer for $850 million in debt due in 2011 at a fixed rate of $1,019.38 per $1,000 in principal. If all debt holders agree to tender their debt, the offering would cost Elan $866.4 million.

To raise more cash, Elan also said it plans to sell $600 million in new debt due 2016.

Regarding the SEC issue, U.S. stock regulators have asked Elan to provide records related to the July 31, 2008 announcement of two Tysabri-related progressive multifocal leukoencephalopathy (PML) cases as well as records relating to the presentation of phase 2 trial data for bapineuzumab at the International Conference of Alzheimer's Diseaseon the July 29, 2008

Handicapping Third Quarter Biotech Earnings

IMS Health released prescription drug sales data for August this morning. Trends continue to show healthy third-quarter gains for Gilead Sciences ( GILD - Get Report) and Amgen ( AMGN - Get Report). Sales trends point to below-expectation results in the third quarter for Biogen Idec ( BIIB - Get Report) and Genzyme ( GENZ).

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.